Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes clinical trials
Its developmentBy Cartesian Therapeutics, step by step6 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- Descartes-08
- 5
Studies by the year they started
6 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 0
Cartesian Therapeutics (6)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes.
- Dec 2026Descartes-08 for Patients With Systemic Lupus ErythematosusPhase 2 · Cartesian Therapeutics
- Nov 2027Descartes-08 in Autoantibody MyositisPhase 2 · Cartesian Therapeutics
Studies
Open first, then newest update. How each study uses Autologous Anti-BCMA-CAR-mRNA-transfected CD8+ T-lymphocytes is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- Descartes-08 in Autoantibody MyositisRecruitingPhase 2Cartesian TherapeuticsNCT07391605Written as Descartes-08How we know
- Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune DisordersRecruitingPhase 1/2Cartesian TherapeuticsNCT07089121Written as Descartes-08How we know
- Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)Active, not recruitingPhase 2Cartesian TherapeuticsNCT04146051Written as Descartes-08How we know
- Descartes-08 for Patients With Systemic Lupus ErythematosusActive, not recruitingPhase 2Cartesian TherapeuticsNCT06038474Written as Descartes-08How we know
- Descartes-08 Consolidation Treatment in Patients With High-Risk Multiple Myeloma High-Risk Multiple Myeloma Who Have Residual Disease After Induction TherapyTerminatedPhase 2Cartesian TherapeuticsNCT04816526Written as Descartes 08How we know
- Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With MyelomaTerminatedPhase 1Cartesian TherapeuticsNCT03448978Written as Descartes-08How we know